170 related articles for article (PubMed ID: 38340948)
21. Distinct effects of V617F and exon12-mutated JAK2 expressions on erythropoiesis in a human induced pluripotent stem cell (iPSC)-based model.
Nilsri N; Jangprasert P; Pawinwongchai J; Israsena N; Rojnuckarin P
Sci Rep; 2021 Mar; 11(1):5255. PubMed ID: 33664283
[TBL] [Abstract][Full Text] [Related]
22. Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms.
Sharma V; Wright KL; Epling-Burnette PK; Reuther GW
Front Immunol; 2020; 11():604142. PubMed ID: 33329600
[TBL] [Abstract][Full Text] [Related]
23. JAK2 V617F-dependent upregulation of PU.1 expression in the peripheral blood of myeloproliferative neoplasm patients.
Irino T; Uemura M; Yamane H; Umemura S; Utsumi T; Kakazu N; Shirakawa T; Ito M; Suzuki T; Kinoshita K
PLoS One; 2011; 6(7):e22148. PubMed ID: 21789226
[TBL] [Abstract][Full Text] [Related]
24. Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells.
Fiskus W; Verstovsek S; Manshouri T; Smith JE; Peth K; Abhyankar S; McGuirk J; Bhalla KN
Mol Cancer Ther; 2013 May; 12(5):577-88. PubMed ID: 23445613
[TBL] [Abstract][Full Text] [Related]
25. SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm.
Yang Y; Abbas S; Sayem MA; Dutta A; Mohi G
Blood Cancer J; 2023 Nov; 13(1):171. PubMed ID: 38012156
[TBL] [Abstract][Full Text] [Related]
26. Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms.
Anand S; Stedham F; Gudgin E; Campbell P; Beer P; Green AR; Huntly BJ
Blood; 2011 Aug; 118(6):1610-21. PubMed ID: 21653937
[TBL] [Abstract][Full Text] [Related]
27. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.
Brecqueville M; Rey J; Bertucci F; Coppin E; Finetti P; Carbuccia N; Cervera N; Gelsi-Boyer V; Arnoulet C; Gisserot O; Verrot D; Slama B; Vey N; Mozziconacci MJ; Birnbaum D; Murati A
Genes Chromosomes Cancer; 2012 Aug; 51(8):743-55. PubMed ID: 22489043
[TBL] [Abstract][Full Text] [Related]
28. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
29. Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms.
Gurska LM; Okabe R; Schurer A; Tong MM; Soto M; Choi D; Ames K; Glushakow-Smith S; Montoya A; Tein E; Miles LA; Cheng H; Hankey-Giblin P; Levine RL; Goel S; Halmos B; Gritsman K
Clin Cancer Res; 2023 Mar; 29(5):943-956. PubMed ID: 36537918
[TBL] [Abstract][Full Text] [Related]
30. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis.
Shimizu T; Kubovcakova L; Nienhold R; Zmajkovic J; Meyer SC; Hao-Shen H; Geier F; Dirnhofer S; Guglielmelli P; Vannucchi AM; Feenstra JD; Kralovics R; Orkin SH; Skoda RC
J Exp Med; 2016 Jul; 213(8):1479-96. PubMed ID: 27401344
[TBL] [Abstract][Full Text] [Related]
31. [Clinical impact of gene mutations on myeloproliferative neoplasms in Japan].
Morishita S
Rinsho Ketsueki; 2021; 62(8):1060-1069. PubMed ID: 34497192
[TBL] [Abstract][Full Text] [Related]
32. Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms.
Hinze A; Rinke J; Crodel CC; Möbius S; Schäfer V; Heidel FH; Hochhaus A; Ernst T
Br J Haematol; 2023 Jul; 202(2):308-317. PubMed ID: 37139709
[TBL] [Abstract][Full Text] [Related]
33. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.
Vainchenker W; Kralovics R
Blood; 2017 Feb; 129(6):667-679. PubMed ID: 28028029
[TBL] [Abstract][Full Text] [Related]
34. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Pasca S; Chifotides HT; Verstovsek S; Bose P
Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
[TBL] [Abstract][Full Text] [Related]
35. JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms.
Rao TN; Hansen N; Hilfiker J; Rai S; Majewska JM; Leković D; Gezer D; Andina N; Galli S; Cassel T; Geier F; Delezie J; Nienhold R; Hao-Shen H; Beisel C; Di Palma S; Dimeloe S; Trebicka J; Wolf D; Gassmann M; Fan TW; Lane AN; Handschin C; Dirnhofer S; Kröger N; Hess C; Radimerski T; Koschmieder S; Čokić VP; Skoda RC
Blood; 2019 Nov; 134(21):1832-1846. PubMed ID: 31511238
[TBL] [Abstract][Full Text] [Related]
36. JAK2-V617F is a negative regulation factor of SHIP1 protein and thus influences the AKT signaling pathway in patients with Myeloproliferative neoplasm (MPN).
Glück M; Dally L; Jücker M; Ehm P
Int J Biochem Cell Biol; 2022 Aug; 149():106229. PubMed ID: 35609769
[TBL] [Abstract][Full Text] [Related]
37. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
Asada S; Kitamura T
Int J Hematol; 2019 Aug; 110(2):179-186. PubMed ID: 30515738
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms.
Meyer SC
Hematol Oncol Clin North Am; 2017 Aug; 31(4):627-642. PubMed ID: 28673392
[TBL] [Abstract][Full Text] [Related]
39. [Clinical application of gene mutation information in myeloproliferative neoplasms].
Takenaka K
Rinsho Ketsueki; 2019; 60(6):610-618. PubMed ID: 31281152
[TBL] [Abstract][Full Text] [Related]
40. miR-433 is aberrantly expressed in myeloproliferative neoplasms and suppresses hematopoietic cell growth and differentiation.
Lin X; Rice KL; Buzzai M; Hexner E; Costa FF; Kilpivaara O; Mullally A; Soares MB; Ebert BL; Levine R; Licht JD
Leukemia; 2013 Feb; 27(2):344-52. PubMed ID: 22864358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]